Table 1.

Clinical characteristics for all men and by ERG overexpression status among 1,180 men treated with radical prostatectomy for prostate cancer, Physicians' Health Study, and Health Professionals Follow-Up Study cohorts 1983–2011

CharacteristicAll menERG-negativeERG positive% ERG positivePa
Number1,18059658449%
Mean follow-up time (years ± SD)12.6 ± 4.512.2 ±4.213.0 ±4.7<0.01
Mean age at diagnosis (years ± SD)65.4 ± 5.965.6 ±5.965.2 ±5.90.17
Pathological tumor stage
 T2 N0/Nx818 (72%)430 (75%)388 (68%)47%
 T3 N0/Nx290 (25%)130 (23%)160 (28%)55%
 T4/N1/M134 (3%)12 (2%)22 (4%)65%<0.01
Gleason sum
 2–6256 (22%)135 (23%)121 (21%)47%
 3+4438 (37%)204 (34%)234 (40%)53%
 4+3268 (23%)143 (24%)125 (21%)47%
 8–10218 (18%)114 (19%)104 (18%)48%0.58
PSA level at diagnosis
 <4132 (12%)56 (10%)76 (14%)58%
 4–<10641 (60%)322 (60%)319 (60%)50%
 ≥10293 (27%)160 (30%)133 (25%)45%0.02
Lethal prostate cancerb
 No1,095 (93%)553 (93%)542 (93%)50%
 Yes85 (7%)43 (7%)42 (7%)49%0.99
Biochemical recurrence
 No914 (77%)462 (78%)452 (77%)49%
 Yes266 (23%)134 (22%)132 (23%)50%0.96
All-cause mortalityc
 No869 (74%)435 (73%)434 (74%)50%
 Yes311 (26%)161 (27%)150 (26%)48%0.60

NOTE: Numbers may not add up to 1,180 because men with missing information for a characteristic are not included in that characteristic.

  • aP values are based on t test for follow-up time and age at diagnosis; Cochran–Armitage trend test for tumor stage, Gleason sum, and PSA level at diagnosis; χ2 test for lethal prostate cancer, biochemical recurrence, and all-cause mortality.

  • bLethal prostate cancer includes metastases to distant organs or bone, and prostate cancer death.

  • cAll-cause mortality includes prostate cancer death and death due to any other cause.